HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: New implications for atherosclerosis

Atherosclerosis

Volumn 172, Issue 1, 2004, Pages 85-93

  Yilmaz, Atilla ^a   Reiss, Christine ^a   Tantawi, Omeima ^a   Weng, Alexander ^a   Stumpf, Christian ^a   Raaz, Dorette ^a   Ludwig, Josef ^a   Berger, Thomas ^a   Steinkasserer, Alexander ^a   Daniel, Werner G ^a   Garlichs, Christoph D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Atherosclerosis; Dendritic cells; Immunology; Inflammation; Statins

Indexed keywords

ATORVASTATIN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; MEVALONIC ACID; PROSTAGLANDIN E2; SIMVASTATIN; STATIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; ATHEROSCLEROSIS; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; DENDRITIC CELL; HUMAN; HUMAN CELL; INCUBATION TIME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE;

EID: 9144222216     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.10.002     Document Type: Article

References (30)

1. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91:2002;281-291.
2. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J.et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
3. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245-3287.
4. Bobryshev Y.V., Lord R.S. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. Arch. Histol. Cytol. 58:1995;307-322.
5. Bobryshev Y.V., Lord R.S. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc. Res. 29:1995;689-696.
6. Bobryshev Y.V., Lord R.S. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc. Res. 37:1998;799-810.
7. Alderman C.J., Bunyard P.R., Chain B.M., Foreman J.C., Leake D.S., Katz D.R. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro- environment? Cardiovasc. Res. 55:2002;806-819.
8. Coutant F., Perrin-Cocon L., Agaugue S., Delair T., Andre P., Lotteau V. Mature dendritic cell generation promoted by lysophosphatidylcholine. J. Immunol. 169:2002;1688-1695.
9. Aicher A., Heeschen C., Mohaupt M., Cooke J.P., Zeiher A.M., Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation. 107:2003;604-611.
10. Nahmod K.A., Vermeulen M.E., Raiden S., Salamone G., Gamberale R., Fernandez-Calotti P.et al. Control of dendritic cell differentiation by angiotensin II. FASEB J. 17:2003;491-493.
11. Morita R., Ukyo N., Furuya M., Uchiyama T., Hori T. Atrial natriuretic peptide polarizes human dendritic cells toward a th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor a. J. Immunol. 170:2003;5869-5875.
12. Weis M., Schlichting C.L., Engleman E.G., Cooke J.P. Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler. Thromb. Vasc. Biol. 22:2002;1817-1823.
13. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
14. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res. 47:2000;648-657.
15. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21:2001;1712-1719.
16. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
17. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933.
18. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:2000;1399-1402.
19. Mach F. Immunosuppressive effects of statins. Atheroscler. Suppl. 3:2002;17-20.
20. Romani N., Reider D., Heuer M., Ebner S., Kampgen E., Eibl B.et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods. 196:1996;137-151.
21. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E. et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:1997;3135-3142.
22. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods. 171:1994;131-137.
23. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23:2002;445-449.
24. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83:1998;683-690.
25. Hernandez-Perera O., Perez-Sala D., Soria E., Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ. Res. 87:2000;616-622.
26. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(kip1). J. Biol. Chem. 274:1999;21926-21931.
27. Kobayashi M., Azuma E., Ido M., Hirayama M., Jiang Q., Iwamoto S.et al. A pivotal role of Rho GTPase in the regulation of morphology and function of dendritic cells. J. Immunol. 167:2001;3585-3591.
28. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc. Natl. Acad. Sci. USA. 97:2000;6930-6932.
29. Wagner A.H., Gebauer M., Guldenzoph B., Hecker M. 3-hydroxy-3- methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22:2002;1784-1789.
30. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M.et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:1995;621-627.